Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint Inhibitors

被引:7
作者
Khalid, Ahmed Bilal [1 ]
Calderon, Gerardo [1 ]
Jalal, Shadia, I [2 ]
Durm, Greg A. [2 ]
机构
[1] Indiana Univ Sch Med, Dept Internal Med, 1120 West Michigan St,Gatch Hall 630, Indianapolis, IN 46202 USA
[2] Indiana Univ, Meivin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN 46204 USA
来源
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2022年 / 20卷 / 12期
关键词
IPILIMUMAB; NIVOLUMAB;
D O I
10.6004/jnccn.2022.7064
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Immune checkpoint inhibitors (ICIs) have been proven to be very effective in the treatment of multiple cancers. They have a unique side-effect profile distinct from conventional chemotherapy that can manifest as immune-related adverse events (irAEs). With expanding ICI use, clinicians will increasingly encounter irAEs, and thus adequate physician knowledge on their recognition and management is crucial. Methods: To assess physician knowledge of irAEs due to ICIs, an online survey was administered to resident physicians in internal medicine (IM), emergency medicine, and family medicine (FM), as well as to faculty physicians in IM and FM. Results: We sent the survey to 413 physicians and received responses from 155 (38%), of which 110 were residents and 45 were faculty. Pembrolizumab was identified as an ICI by 79% of physicians, nivolumab by 64%, and ipilimumab by 55%. Twenty-five percent incorrectly thought infliximab and adalimumab were ICIs. Most physicians (93%) were able to identify the gastrointestinal tract as an irAE site, whereas only 57% and 67% were able to identify cardiovascular and renal systems as irAE sites, respectively. A total of 59% believed steroids negatively affect efficacy of ICIs and should be used with caution to treat irAEs, 65% incorrectly thought endocrinopathies due to irAEs are usually reversible, and 45% of FM residents considered antibiotics as the mainstay of treatment in ICI-mediated colitis. On a self-rated scale from 0 to 100, the median comfort level for all physicians in recognizing irAEs was 15 and for treatment of irAEs was 10. Conclusions: Significant knowledge gaps exist among residents and faculty physicians across multiple specialties regarding the recognition and treatment of irAEs due to ICIs. Given that these physicians are usually the first point of contact with patients, physician education on identification and treatment of irAEs is needed. Early detection of these toxicities is critical for their resolution.
引用
收藏
页码:1316 / 1320
页数:5
相关论文
共 19 条
[1]   A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors [J].
Arnaud-Coffin, Patrick ;
Maillet, Denis ;
Gan, Hui K. ;
Stelmes, Jean-Jacques ;
You, Benoit ;
Dalle, Stephane ;
Peron, Julien .
INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (03) :639-648
[2]   Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis [J].
Bertrand, Anne ;
Kostine, Marie ;
Barnetche, Thomas ;
Truchetet, Marie-Elise ;
Schaeverbeke, Thierry .
BMC MEDICINE, 2015, 13
[3]   A nationwide survey among emergency physicians and oncologists to improve the management of immune checkpoint inhibitors toxicity [J].
Giamello, Jacopo Davide ;
Lauria, Giuseppe ;
Antonuzzo, Andrea ;
Bossi, Paolo ;
Lorenzati, Bartolomeo ;
Numico, Gianmauro .
SUPPORTIVE CARE IN CANCER, 2022, 30 (08) :6365-6368
[4]   Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support [J].
Harris, Paul A. ;
Taylor, Robert ;
Thielke, Robert ;
Payne, Jonathon ;
Gonzalez, Nathaniel ;
Conde, Jose G. .
JOURNAL OF BIOMEDICAL INFORMATICS, 2009, 42 (02) :377-381
[5]   Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs [J].
Haslam, Alyson ;
Prasad, Vinay .
JAMA NETWORK OPEN, 2019, 2 (05)
[6]   Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center [J].
Horvat, Troy Z. ;
Adel, Nelly G. ;
Thu-Oanh Dung ;
Momtaz, Parisa ;
Postow, Michael A. ;
Callahan, Margaret K. ;
Carvajal, Richard D. ;
Dickson, Mark A. ;
D'Angelo, Sandra P. ;
Woo, Kaitlin M. ;
Panageas, Katherine S. ;
Wolchok, Jedd D. ;
Chapman, Paul B. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28) :3193-+
[7]   Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA [J].
Kalinich, Mark ;
Murphy, William ;
Wongvibulsin, Shannon ;
Pahalyants, Vartan ;
Yu, Kun-Hsing ;
Lu, Chenyue ;
Wang, Feicheng ;
Zubiri, Leyre ;
Naranbhai, Vivek ;
Gusev, Alexander ;
Kwatra, Shawn G. ;
Reynolds, Kerry L. ;
Semenov, Yevgeniy R. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)
[8]  
Kulkarni A, 2020, J CLIN ONCOL, V38
[9]   Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives [J].
Lim, Sun Min ;
Hong, Min Hee ;
Kim, Hye Ryun .
IMMUNE NETWORK, 2020, 20 (01)
[10]   Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma [J].
Lipson, Evan J. ;
Drake, Charles G. .
CLINICAL CANCER RESEARCH, 2011, 17 (22) :6958-6962